Stroke
Conditions
Interventions
Trade Name: Persantin
Pharmaceutical Form: Capsule*
Trade Name: dipyridamol
Product Name: dipyridamol
Pharmaceutical Form: Tablet
Trade Name: Acetylsalicylzuur (acetyl salicylic acid)
Product Name:
Sponsors
None listed
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: age over 18 CVA or TIA Patients starting treatment with acetylsalicylic acid combined with dipyridamole according to Dutch treatment standards Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Patients not able to start treatment with acetylsalicylic acid combined with dipyridamole according to Dutch treatment standards
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To determine the best dose escalation scheme of dipyridamole added to acetylsalicylic acid, based on the side-effect headache, in patients starting secondary preventive therapy for stroke ;Secondary Objective: How often do patients stop therapy because of headaches? Do in-hospital patient more often get a Ct-scan or MRI? Is there a difference in headaches between CVA patients and TIA patients? Is it possible to identify a specific group of patients that benefits more from one dose escalation scheme than an other group?;Primary end point(s): Headache frequency | — |
Countries
Netherlands
Outcome results
None listed